Thyroarytenoid botulinum toxin injection for refractory laryngeal contact granuloma

BackgroundAlthough there are many treatments for laryngeal contact granuloma (LCG), some patients still fail treatment. Botulinum toxin A injection vocal cords may be a salvage therapy.ObjectivesTo study the efficacy of thyroarytenoid botulinum toxin A injection for the treatment of refractory LCG.Material and methodsFrom May 2021 to March 2022, 23 male patients with refractory idiopathic LCG were treated by injection of botulinum toxin A into the thyroarytenoid muscle via the thyrohyoid membrane approach. Inspiratory-phase laryngoscopy images were collected before treatment and 3 months after injection treatment. The lesion size was evaluated with the Farwell granuloma endoscopic grading system and Image J software.ResultsThe average age of 23 patients was 49 years. The dose of botulinum toxin injection ranged from 2.5 to 5 units. Three months after injection, 17 patients were cured, 2 patients showed marked improvement, and 4 patients did not experience any effect. The total efficacy rate was 82.61% (19/23), and no serious complications occurred. Almost all patients experienced hoarseness within one week after injection; they gradually recovered after one month, and their voice returned to baseline at 3 months.ConclusionsThyroarytenoid botulinum toxin injection is an effective method for resolving refractory LCG.     

硬膜下积液治疗经验总结（附27例临床分析）

目的总结不同类型硬膜下积液治疗经验。 方法对解放军总医院第六医学中心神经外科自2009年1月至2014年10月手术治疗并完整随访的27例硬膜下积液患者进行回顾性分析。根据术前影像学特征鉴别积液是否为血性，将患者分为血性硬膜下积液患者（9例）和非血性硬膜下积液患者（18例）。根据积液是否为血性选择个性化治疗方案，观察其疗法。 结果9例血性硬膜下积液患者接受钻孔外引流手术，8例积液消退，另外1例无效，之后接受硬膜下腹腔分流后治愈。非血性硬膜下积液患者中14例接受硬膜下腹腔分流，12例有效，2例术后出现脑积水，经脑室-腹腔分流术治愈；2例术前合并脑积水接受脑室-腹腔分流术，均有效；另外2例最初接受积液外引流，无效，之后行硬膜下腹腔分流后积液消退。 结论对于硬膜下积液患者，术前需仔细评估积液是否为血性，是否合并脑积水。血性积液采取钻孔外引流，非血性积液采取硬膜下腹腔分流，合并脑积水的积液采取脑室-腹腔分流手术方式，给予个体化治疗，可获得满意疗效。     

Effect of Dexmedetomidine infusion during hip fracture surgery on hemodynamic parameters and blood loss: A triple-blinded Randomized Clinical Trial

Introduction In this study, we aim to assess the intra-operative effect of dexmedetomidine administration on the hemodynamic parameters and bleeding volume during hip fracture surgery.Patients and methods we designed and implemented a triple-blinded randomized clinical trial to objectively compare the effects of 0.5 µg/kg/h infusion of dexmedetomidine with placebo (equal amount of normal saline) during hip fracture surgery. All included cases were between 30 and 70 years old and underwent surgery for fixation of a proximal femur fracture from September 26, 2020 until February 15, 2021. They were all ASA class I or II with preoperative hemoglobin levels of 10 mg/dL or higher. Surgical blood loss and hemodynamic parameters were documented.Results 76 patients were enrolled. There were no significant differences in baseline patient characteristics. The bleeding rate was 620 ± 190.0 mL for the normal saline group and 476 ± 177.98 mL in the dexmedetomidine group (P = 0.04). No significant effect on hemodynamic parameters was observed.Conclusion Based on the current study, intravenous infusion of dexmedetomidine during hip fracture surgery under general anesthesia reduced the amount of intraoperative bleeding without causing any significant hemodynamic disturbances.Registration number IRCT20191222045857N1 (Iranian Registry of Clinical Trials)     

经导管肝动脉化疗栓塞联合立体定向放射治疗对不可切除原发性肝癌的疗效分析

目的:分析经导管肝动脉化疗栓塞(TACE)联合立体定向放射治疗(SRT)治疗不可切除原发性肝癌的疗效及不良反应。方法:选取56例不可切除肝癌患者,根据治疗方法的不同将其分为TACE联合SRT组(联合组,32例)和单纯TACE组(单纯组,24例),联合组采用TACE联合SRT方法,单纯组采用单纯TACE治疗方法。依据实体瘤疗效评价标准(RECIST)1.1版进行近期疗效评价,观察记录治疗相关不良反应。结果:联合组近期有效率为84.3%,1年局部控制率为71.9%,单纯组近期有效率为79.2%,1年局部控制率为45.8%,近期有效率两组间差异无统计学意义(x~2=0.254,P>0.05),1年局部控制率联合组显著优于单纯组,差异有统计学意义(x~2=3.899,P<0.05)。两组间不良反应差异无统计学意义。结论:SRT联合TACE治疗不可切除肝癌局部控制率高,耐受性好,可以作为一种可靠而有效的治疗方法。     

模拟器训练在实施股动脉穿刺点ExoSealTM封堵止血系统操作的多中心对照研究

背景与目的：介入手术已成为血管外科的主要治疗手段,对于手术直接相关的股动脉穿刺点封堵处理是手术操作收尾的一个重要环节。鉴于国内外目前尚缺乏关于封堵止血系统模拟器训练应用效果的高级别证据,本研究旨在评估模拟器训练在实施股动脉穿刺点ExoSealTM封堵止血系统操作的临床应用效果以及在血管介入操作基础教学培训中的应用价值。 方法：采用前瞻性对照设计,选择2020年5月—2020年10月7个中心的8名血管介入医师分别用两种不同方式进行封堵操作培训。4名血管介入医师通过阅读ExoSealTM说明书和观看视频进行培训（对照组）,另4名血管介入医师的培训方式为在前者基础上增加专业人员指导下的模拟器使用（研究组）。培训结束后,在主诊医师监管下,每名医师对接受血管介入手术,并在股总动脉使用6 F鞘管的患者,采用ExoSealTM封堵止血系统对穿刺点进行封堵。两组医师各操作50例患者,比较两组的操作时间、出血量、器械成功率、股动脉栓塞发生率、二次干预率、24 h内发生血肿率。 结果：研究组在ExoSealTM封堵止血系统操作中,所需的操作时间和出血量均少于对照组（24.50 s vs. 30.00 s,P=0.003;8.60 mL vs. 11.22 mL,P=0.019）。研究组的器械成功率（98.0%）高于对照组（96.0%）,但差异无统计学意义（P=0.558）。两组均无动脉栓塞、二次干预和24 h内发生血肿情况。 结论：ExoSealTM封堵止血系统模拟器的训练能够提高股动脉封堵的安全性和有效性。该模拟器的训练应常规用于血管介入操作的基础教学培训中。     

Releasing of The White Paper on Medical Imaging Artificial Intelligence in China

In the afternoon of March 26,2019, The White Paper on Medical Imaging Artificial Intelligence in China was officially released in Beijing by the Chinese Innovative Alliance of Industry, Education, Research and Application of Artificial Intelligence for Medical Imaging (CAIERA). The white paper was co-operatively written by the medical imaging experts from the tertiary Chinese hospitals, the scientific experts from AI research institutions and the leading AI medical enterprises in China. The contents of the white paper not only cover the up-to-date application of AI in medical field, the latest advances of AI algorithms in medical image processing, the data requirement for medical AI development, and the current situation of structured data, but also expatiate the goal and challenge of clinical application for medical imaging AI development in 16 medical subject areas, which helps to identify the demands and opportunities for the AI industry. Forty representative enterprises of AI medical imaging in China were introduced in the white paper. The white paper points out the three key problems in development of AI products: the robustness, ease of usage and data security, which provides guidance of direction and strategy for the enterprises. Particularly, in view of the national policy on developing AI, the white paper gives a profound analysis on the challenges and the opportunities that medical imaging AI is facing. These contents agglomerate the cutting-edge efforts of experts in the industry-academia-research-application chain of medical AI, represent the mainstream voice of the society in China. The White Paper will play a guiding role in understanding the market demands and establishing standardized systems in the path of landing AI products in the field medical imaging. Full text of the White paper is publicly accessible from the CAIERA website, or by scanning the 2D code in the article.     

13例新生儿红斑狼疮的临床特征、皮损后遗表现

【摘要】 目的 探讨新生儿红斑狼疮（NLE）的皮损后遗表现，分析可能的相关因素。方法 回顾2016—2020年首都儿科研究所附属儿童医院皮肤科收集并长期随访的13例NLE，分析患儿及母亲临床特征、患儿皮损后遗表现。结果 13例皮损发病时间为出生后0 ~ 120 d，平均15 d，随访时间15 ~ 43个月，皮损形态主要为环状红斑、斑丘疹、鳞屑，皮损消退时间2 ~ 18个月（平均7.4个月）。6例皮损消退后出现色素异常表现，3例同时出现色素减退和色素沉着，2例仅有色素减退，1例仅有色素沉着，1例色素减退患儿在随访18个月后色素减退复色，未见毛细血管扩张以及萎缩或瘢痕。8例患儿母亲孕前无异常，4例患儿母亲抗ANA、抗SSA/Ro、抗SSB/La抗体均阳性。结论 NLE的皮肤受累可出现后遗皮肤表现，常见为色素异常，多数长期未消退，应注意患儿母亲可能存在的潜在性免疫系统异常。     

等离子射频辅助双侧声带后端切断术治疗双侧声带麻痹导致的上气道梗阻患者13例

目的 评估内镜下等离子射频辅助双侧声带后端切断术治疗双侧声带麻痹导致上气道梗阻患者的疗效。 方法 回顾性分析13例双侧声带麻痹导致的上气道梗阻患者的病例资料,其中男6例、女7例,27~73岁,所有患者均接受等离子射频辅助双侧声带后端切断术。总结评估该手术的临床疗效。 结果 13例随访时间1年1个月~2年11个月,所有患者无严重并发症发生。一次拔管率为84.44%(10/13),二次手术拔管率为88.89%(11/13),拔管时间1~3个月,中位数1个月,上气道梗阻均未复发。 结论 内镜下等离子射频辅助双侧声带切断术操作简单、手术风险小,同时治疗双侧声带麻痹效果可靠,是双侧声带麻痹导致上气道梗阻的有效治疗方法之一,也可作为其他治疗失败的补救治疗措施。     

Delirium Development After Lung Transplantation: An Intraoperative Assessment

BackgroundThis study aimed to evaluate the relationship between intraoperative hemodynamic and laboratory parameters with postoperative delirium development after lung transplantation.MethodsA total of 77 patients who underwent lung transplantation in a single center were included in the study. Demographic and clinical data recorded at critical intraoperative stages (after induction [T1], after bilateral lungs are dissected [T2], while the patient is ventilated for 1 lung [T3], while the unilateral transplanted lung is ventilated [T4], while bilateral transplanted lungs are ventilated [T5], and after the thorax is closed [T6]), postoperative complications, mechanical ventilation duration, intensive care, and hospitalization durations and mortality rates were recorded.ResultsA total of 83.1% of the 77 patients were male, and the mean (SD) age was 47.56 (12.95) years. The mean body mass index (calculated as weight in kilograms divided by height in meters squared) was 23.30 (3.99), and the median Charles Comorbidity Index (CCI) was 1. The diagnosis of 36.4% of the patients was chronic obstructive pulmonary disease. Delirium was seen in 51.9% of the patients. Age, CCI, intraoperative mean arterial pressure changes, lactate levels, mechanical ventilation duration, and hospital stay were all associated with delirium development.ConclusionAge, CCI, duration of mechanical ventilation, and hospital stay were independent predictors of postoperative delirium development. We believe that our study will be a guide for future prospective randomized controlled studies.     

70例免疫球蛋白辅助治疗老年脓毒症患者效果的研究

目的 探讨免疫球蛋白辅助治疗老年脓毒症患者的疗效,研究死亡患者的临床特征,分析临床指标对患者预后的预测价值。方法 选取2017年1月-2020年5月解放军总医院第六医学中心诊治的140例老年脓毒症患者,常规治疗+免疫球蛋白治疗70例为研究组,常规治疗70例为对照组,评估免疫球蛋白治疗效果及治疗前后临床指标情况。根据患者28 d预后情况分为存活及死亡两亚组,采用受试者工作曲线 (ROC)评价临床指标对患者预后的预测价值。结果 研究组与对照组患者一般情况差异无统计学意义（P>0.05）;研究组28 d死亡率下降,但与对照组比较差异无统计学意义（P>0.05）;免疫球蛋白辅助治疗能更好的降低C反应蛋白（CRP）等炎性指标,差异有统计学意义（P<0.05）;存活和死亡亚组患者临床指标单因素分析,结果示SOFA、APACHEⅡ、乳酸（Lac）、降钙素原（PCT）和血小板差异有统计学意义（P<0.05）;多因素logistic分析示SOFA、APACHEⅡ和Lac是影响预后的独立危险因素;将预测值纳入受试者工作曲线（ROC）,结果显示曲线下面积（AUC）为0.854,95%置信区间为（0.789～0.919）。结论 免疫球蛋白辅助治疗老年脓毒症患者的死亡率下降,但差异无统计学意义;SOFA、APACHEⅡ和Lac对患者预后预测效能较好。